Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.

Excler JL, Delvecchio CJ, Wiley RE, Williams M, Yoon IK, Modjarrad K, Boujelal M, Moorthy VS, Hersi AS, Kim JH; MERS-CoV Vaccine Working Group.

Emerg Infect Dis. 2016 Aug;22(8). doi: 10.3201/eid2208.160229.

2.

Identification of the Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV for the Design of a Genetically Stable Vaccine.

Jimenez-Guardeño JM, Regla-Nava JA, Nieto-Torres JL, DeDiego ML, Castaño-Rodriguez C, Fernandez-Delgado R, Perlman S, Enjuanes L.

PLoS Pathog. 2015 Oct 29;11(10):e1005215. doi: 10.1371/journal.ppat.1005215. eCollection 2015 Oct.

3.

Evaluation of candidate vaccine approaches for MERS-CoV.

Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS.

Nat Commun. 2015 Jul 28;6:7712. doi: 10.1038/ncomms8712.

4.

Understanding the T cell immune response in SARS coronavirus infection.

Janice Oh HL, Ken-En Gan S, Bertoletti A, Tan YJ.

Emerg Microbes Infect. 2012 Sep;1(9):e23. doi: 10.1038/emi.2012.26. Epub 2012 Sep 5. Review.

5.

Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines.

Jiang S, Lu L, Liu Q, Xu W, Du L.

Emerg Microbes Infect. 2012 Aug;1(8):e13. doi: 10.1038/emi.2012.1. Epub 2012 Aug 8. Review.

6.

Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus.

Sutton TC, Subbarao K.

Virology. 2015 May;479-480:247-58. doi: 10.1016/j.virol.2015.02.030. Epub 2015 Mar 16. Review.

7.

The coronavirus nucleocapsid is a multifunctional protein.

McBride R, van Zyl M, Fielding BC.

Viruses. 2014 Aug 7;6(8):2991-3018. doi: 10.3390/v6082991. Review.

8.

Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus.

Yip MS, Leung NH, Cheung CY, Li PH, Lee HH, Daëron M, Peiris JS, Bruzzone R, Jaume M.

Virol J. 2014 May 6;11:82. doi: 10.1186/1743-422X-11-82.

9.

Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.

Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N.

J Virol. 2014 Aug;88(15):8597-614. doi: 10.1128/JVI.00983-14. Epub 2014 May 21.

10.

A decade after SARS: strategies for controlling emerging coronaviruses.

Graham RL, Donaldson EF, Baric RS.

Nat Rev Microbiol. 2013 Dec;11(12):836-48. doi: 10.1038/nrmicro3143. Epub 2013 Nov 11. Review.

11.

Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.

Coughlin MM, Prabhakar BS.

Rev Med Virol. 2012 Jan;22(1):2-17. doi: 10.1002/rmv.706. Epub 2011 Sep 8. Review.

12.

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway.

Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, Dutry I, Callendret B, Escriou N, Altmeyer R, Nal B, Daëron M, Bruzzone R, Peiris JS.

J Virol. 2011 Oct;85(20):10582-97. doi: 10.1128/JVI.00671-11. Epub 2011 Jul 20.

13.

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.

Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y.

Virol J. 2010 Nov 4;7:299. doi: 10.1186/1743-422X-7-299.

14.

T cell epitope specificity and pathogenesis of mouse hepatitis virus-1-induced disease in susceptible and resistant hosts.

Khanolkar A, Fulton RB, Epping LL, Pham NL, Tifrea D, Varga SM, Harty JT.

J Immunol. 2010 Jul 15;185(2):1132-41. doi: 10.4049/jimmunol.0902749. Epub 2010 Jun 16.

15.

A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.

Du L, Zhao G, Chan CC, Li L, He Y, Zhou Y, Zheng BJ, Jiang S.

Viral Immunol. 2010 Apr;23(2):211-9. doi: 10.1089/vim.2009.0090.

16.

Identification of a novel conserved HLA-A*0201-restricted epitope from the spike protein of SARS-CoV.

Lv Y, Ruan Z, Wang L, Ni B, Wu Y.

BMC Immunol. 2009 Dec 3;10:61. doi: 10.1186/1471-2172-10-61.

17.

Protective and pathologic roles of the immune response to mouse hepatitis virus type 1: implications for severe acute respiratory syndrome.

Khanolkar A, Hartwig SM, Haag BA, Meyerholz DK, Epping LL, Haring JS, Varga SM, Harty JT.

J Virol. 2009 Sep;83(18):9258-72. doi: 10.1128/JVI.00355-09. Epub 2009 Jul 1.

18.

Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.

Prabakaran P, Zhu Z, Xiao X, Biragyn A, Dimitrov AS, Broder CC, Dimitrov DS.

Expert Opin Biol Ther. 2009 Mar;9(3):355-68. doi: 10.1517/14712590902763755 . Review. Erratum in: Expert Opin Biol Ther. 2009 Apr;9(4):533.

19.

Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).

Suresh MR, Bhatnagar PK, Das D.

J Pharm Pharm Sci. 2008 Apr 19;11(2):1s-13s.

20.

The spike protein of SARS-CoV--a target for vaccine and therapeutic development.

Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S.

Nat Rev Microbiol. 2009 Mar;7(3):226-36. doi: 10.1038/nrmicro2090. Epub 2009 Feb 9. Review.

Supplemental Content

Support Center